These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

408 related items for PubMed ID: 26500706

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents.
    Li CJ, Liu XJ, Bai L, Yu Q, Zhang QM, Yu P, Yu DM.
    Diabetol Metab Syndr; 2014; 6():69. PubMed ID: 24917890
    [Abstract] [Full Text] [Related]

  • 3. Evaluating the Efficacy, Safety, and Tolerability of Combination Therapy of Dapagliflozin and Linagliptin Over Dapagliflozin and Vildagliptin in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.
    Dharmalingam M, Kumar Sharma S, Prakash V, Maiti A, Kumar R, Murthy LSS, Ramanathan B, Maheshwari S, Naik Kethavath S, Ogale D, Bachubhai PVK, Sonawane AB, Shah V, Suresh M, Chakraborty S, Kumar Manjunath K.
    Cureus; 2024 Apr; 16(4):e58115. PubMed ID: 38738005
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Dipeptidyl Peptidase-4 inhibitors use in type II diabetic patients in a tertiary hospital.
    Mak WY, Nagarajah JR, Abdul Halim H, Ramadas A, Mohd Pauzi Z, Pee LT, Jagan N.
    J Pharm Policy Pract; 2020 Apr; 13():34. PubMed ID: 32566235
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
    Shigematsu E, Yamakawa T, Oba MS, Suzuki J, Nagakura J, Kadonosono K, Terauchi Y.
    J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus.
    Odawara M, Hamada I, Suzuki M.
    Diabetes Ther; 2014 Jun; 5(1):169-81. PubMed ID: 24604395
    [Abstract] [Full Text] [Related]

  • 13. Acarbose Add-on Therapy in Patients with Type 2 Diabetes Mellitus with Metformin and Sitagliptin Failure: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
    Yang HK, Lee SH, Shin J, Choi YH, Ahn YB, Lee BW, Rhee EJ, Min KW, Yoon KH.
    Diabetes Metab J; 2019 Jun; 43(3):287-301. PubMed ID: 30604599
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and Safety of a Fixed-Dose Combination of Vildagliptin and Pioglitazone in Indian Patients With Type 2 Diabetes Mellitus: A Randomized, Open-Label, Comparative, Phase III Study.
    Erande S, Mukhopadhyay J, Dange A, Deogaonkar A, Birla A, Doshi C, Revankar S, B SS, Kumar N, Kadam PV.
    Cureus; 2023 Sep; 15(9):e44548. PubMed ID: 37795066
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of DPP4i as the Fourth Drug in the Management of Type2 Diabetes Mellitus in Asian Indians Poorly Controlled by Use of at least 3 Oral Antidiabetic Drugs.
    Panikar V, Joshi S, Tiwaskar M, Vadgama J, Nasikkar N, Kamat T, Deogaonkar N, Walawalkar S, Sachdev I, Jain C, Modh K, Panikar K, Kulkarni P, Medidar R.
    J Assoc Physicians India; 2019 Aug; 67(8):60-62. PubMed ID: 31562719
    [Abstract] [Full Text] [Related]

  • 16. A Randomized, Double-Blind, Parallel-Group Phase III Trial Investigating the Glycemic Efficacy and Safety Profile of Fixed-Dose Combination Dapagliflozin and Linagliptin Over Linagliptin Monotherapy in Patients with Inadequately Controlled Type 2 Diabetes with Metformin.
    Jain A, Vispute A, Dange A, Naskar A, Mondal A, Vivekanand B, Sharma B, Varade D, Shukla D, Bhatia G, Chaudhari H, Ram Babu K, Gavali O, Sorate S, Bhanushali S, Kothari V, Khandelwal V, Sharma A, Pawar R, Mayabhate M, Shahavi V, Rajput A, Jaiswal M.
    Diabetes Ther; 2024 Jan; 15(1):215-227. PubMed ID: 37957465
    [Abstract] [Full Text] [Related]

  • 17. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
    El Ebrashy I, El Kafrawy N, Raouf R, Yousry D.
    Diabetes Res Clin Pract; 2020 Apr; 162():108042. PubMed ID: 32006641
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of the glucagon-like peptide-1 receptor agonist lixisenatide versus the dipeptidyl peptidase-4 inhibitor sitagliptin in young (<50 years) obese patients with type 2 diabetes mellitus.
    Van Gaal L, Souhami E, Zhou T, Aronson R.
    J Clin Transl Endocrinol; 2014 Jun; 1(2):31-37. PubMed ID: 29159080
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of vildagliptin in clinical practice-results of the PROVIL-study.
    Blüher M, Kurz I, Dannenmaier S, Dworak M.
    World J Diabetes; 2012 Sep 15; 3(9):161-9. PubMed ID: 23125906
    [Abstract] [Full Text] [Related]

  • 20. The Effect of DPP-4 Inhibitors on Metabolic Parameters in Patients with Type 2 Diabetes.
    Choe EY, Cho Y, Choi Y, Yun Y, Wang HJ, Kwon O, Lee BW, Ahn CW, Cha BS, Lee HC, Kang ES.
    Diabetes Metab J; 2014 Jun 15; 38(3):211-9. PubMed ID: 25003075
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.